Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year

Mantle cell lymphoma (MCL) is an infrequent subtype of non-Hodgkin’s lymphoma (NHL) and represents between 4–8% of adult lymphomas. Recently an increase in its incidence to 1–2 cases/100,000 inhabitants/year has been observed. The first line of treatment is based on chemoimmunotherapy and depends on...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrero-Vicent, Carmen, Machado, Isidro, Illueca, Carmen, Avaria, Amparo, Salazar, Claudia, Hernandez, Abraham, Sandiego, Sergio, Lavernia, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817526/
https://www.ncbi.nlm.nih.gov/pubmed/27110283
http://dx.doi.org/10.3332/ecancer.2016.627
Descripción
Sumario:Mantle cell lymphoma (MCL) is an infrequent subtype of non-Hodgkin’s lymphoma (NHL) and represents between 4–8% of adult lymphomas. Recently an increase in its incidence to 1–2 cases/100,000 inhabitants/year has been observed. The first line of treatment is based on chemoimmunotherapy and depends on age and the initial stage at diagnosis. There are no second line or successive treatments. There are currently several drugs available that provide acceptable results.

Ejemplares similares